Isolated limb perfusion: Distinct tourniquet and tumor necrosis factor effects on the early hemodynamic response

Archives of Surgery

Volumn 138, Issue 1, 2003, Pages 17-25

  Christoforidis, Dimitri ^a   Chassot, Pierre Guy ^a   Mosimann, François ^a   Lienard, Danielle ^a   Brunstein, Flavia ^b   Bejko, Dritan ^c   Lejeune, Ferdy J ^a   Chiolero, Rene ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CATECHOLAMINE; FOTEMUSTINE; GAMMA INTERFERON; INTERLEUKIN 6; MELPHALAN; TUMOR NECROSIS FACTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BODY TEMPERATURE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HEART INDEX; HEART RATE; HEMODYNAMIC MONITORING; HEMODYNAMICS; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LIMB PERFUSION; LIMB TUMOR; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; SWAN GANZ CATHETER; SYSTEMIC VASCULAR RESISTANCE; TOURNIQUET; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

EID: 0037225741     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.138.1.17     Document Type: Article

References (44)

1. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975;72:3666-3670.
2. Bartsch HH, Pfizenmaier K, Schroder M, Nagel GA. Systemic versus local therapy with recombinant tumor necrosis factor-alpha (r-TNF-alpha) in patients with advanced tumors [in German]. Onkologie. 1989;12:136-141.
3. Creaven PJ, Brenner DE, Cowens JW, et al. A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days. Cancer Chemother Pharmacol. 1989;23:186-191.
4. Zamkoff KW, Newman NB, Rudolph AR, Young J, Poiesz BJ. A phase I trial of subcutaneously administered recombination tumor necrosis factor to patients with advanced malignancy. J Biol Response Mod. 1989;8:539-552.
5. Wiedenmann B, Reichardt P, Rath U, et al. Phase-I trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic carcinomas. J Cancer Res Clin Oncol. 1989;115:189-192.
6. Creech OJ. Chemotherapy of cancer: Regional perfusion using an extracorporeal circuit. Ann Surg. 1958;148:616-632.
7. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 1992;10:52-60.
8. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Evidence for the involvement of endothelial cell integrin αVβ3 in the disruption of the tumor vasculature induced by TNF and IFN-γ. Nat Med. 1998;4:408-414.
9. Eggimann P, Chiolero R, Chassot PG, Lienard D, Gerain J, Lejeune F. Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs. Chest. 1995;107:1074-1082.
10. Fawcett WJ, Hill S, Sheldon J, et al. Hemodynamic changes and circulating recombinant tumor necrosis factor-α concentrations in a patient undergoing isolated limb perfusion. Crit Care Med. 1993;21:796-800.
11. Villani F, Galimberti M, Mazzola G, et al. Cardiac and pulmonary effects of alpha tumor necrosis factor administered by isolation perfusion. Tumori. 1995;81:197-200.
12. Zwaveling JH, Maring JK, Clarke FL, et al. High plasma tumor necrosis factor (TNF)-α concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-α, interferon-γ, and melphalan. Crit Care Med. 1996;24:765-770.
13. Eggermont AM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas: The cumulative multicenter European experience. Ann Surg. 1996;224:756-765.
14. Eggermont AM, Schraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-α in combination with interferon-γ and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial. J Clin Oncol. 1996;14:2653-2665.
15. Lienard D, Eggermont AM, Schraffordt Koops H, et al. Isolated perfusion of the limb with high-dose tumour necrosis factor-α (TNF-α), interferon-γ (IFN-γ) and melphalan for melanoma stage III: Results of a multi-centre pilot study. Melanoma Res. 1994;4(suppl 1):21-26.
16. Lienard D, Eggermont AM, Koops HS, et al. Isolated limb perfusion with tumour necrosis factor-α and melphalan with or without interferon-γ for the treatment of in-transit melanoma metastases: A multicentre randomized phase II study. Melanoma Res. 1999;9:491-502.
17. Lejeune FJ, Fujol N, Lienard D, et al. Limb salvage by neoadjuvant isolated perfusion with TNFα and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol. 2000;26:669-678.
18. Hoekstra HJ, Naujocks T, Schraffordt Koops H, et al. Continuous leakage monitoring during hyperthermic isolated regional perfusion of the lower limb: Techniques and results. Region Cancer Treat. 1992;4:301-304.
19. Klaase JM, Kroon BB, van Geel AN, Eggermont AM, Franklin HR. Systemic leakage during isolated limb perfusion for melanoma. Br J Surg. 1993;80:1124-1126.
20. Ganz W, Donoso R, Marcus HS, Forrester JS, Swan HJ. A new technique for measurement of cardiac output by thermodilution in man. Am J Cardiol. 1971;27:392-396.
21. Espevik T, Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods. 1986;95:99-105.
22. Gerain J, Lienard D, Pampallona S, et al. Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion. Cytokine. 1997;9:1034-1042.
23. Valli H, Rosenberg PH, Kytta J, Nurminen M. Arterial hypertension associated with the use of a tourniquet with either general or regional anaesthesia. Acta Anaesthesiol Scand. 1987;31:279-283.
24. Kaufman RD, Walts LF. Tourniquet-induced hypertension. Br J Anaesth. 1982;54:333-336.
25. Crews JC, Cahall M, Behbehani MM. The neurophysiologic mechanisms of tourniquet pain: The activity of neurons in the rostroventral medulla in the rat. Anesthesiology. 1994;81:730-736.
26. Estebe JP, Malledant Y. Pneumatic tourniquets in orthopedics. Ann Fr Anesth Reanim. 1996;15:162-178.
27. Girardis M, Milesi S, Donato S, et al. The hemodynamic and metabolic effects of tourniquet application during knee surgery. Anesth Analg. 2000;91:727-731.
28. Modig J, Kolstad K, Wigren A. Systemic reactions to tourniquet ischaemia. Acta Anaesthesiol Scand. 1978;22:609-614.
29. Parmet JL, Horrow JC, Berman AT, Miller F, Pharo G, Collins L. The incidence of large venous emboli during total knee arthroplasty without pneumatic tourniquet use. Anesth Analg. 1998;87:439-444.
30. Thijs LG, Schneider AJ, Groeneveld AB. The haemodynamics of septic shock. Intensive Care Med. 1990;16(suppl 3):S182-S186.
31. Jahr J, Grande PO. In vivo effects of tumor necrosis factor-α on capillary permeability and vascular tone in a skeletal muscle Acta Anaesthesiol Scand. 1996;40:256-261.
32. Takahashi K, Ando K, Ono A, Shimosawa T, Ogata E, Fujita T. Tumor necrosis factor-α induces vascular hyporesponsiveness in Sprague-Dawley rats. Life Sci. 1992;50:1437-1444.
33. Hollenberg SM, Cunnion RE, Parrillo JE. The effect of tumor necrosis factor on vascular smooth muscle: In vitro studies using rat aortic rings. Chest. 1991;100:1133-1137.
34. Naziri W, Joshua IG. Role of tumor necrosis factor-α in small intestinal microcirculation. Am Surg. 1998;64:203-210.
35. Kilbourn RG, Gross SS, Jubran A, et al. NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: Implications for the involvement of nitric oxide. Proc Natl Acad Sci U S A. 1990;87:3629-3632.
36. Baudry N, Vicaut E. Role of nitric oxide in effects of tumor necrosis factor-α on microcirculation in rat. J Appl Physiol. 1993;75:2392-2399.
37. Johns DG, Webb RC. TNF-α-induced endothelium-independent vasodilation: A role for phospholipase A2-dependent ceramide signaling. Am J Physiol. 1998;275(pt 2):H1592-H1598.
38. Drapier JC, Wietzerbin J, Hibbs JB Jr. Interferon-γ and tumor necrosis factor induce the L-arginine-dependent cytotoxic effector mechanism in murine macrophages. Eur J Immunol. 1988;18:1587-1592.
39. Thiemermann C, Wu CC, Szabo C, Perretti M, Vane JR. Role tumour necrosis factor in the induction of nitric oxide synthase in a rat model of endotoxin shock. Br J Pharmacol. 1993;110:177-182.
40. Nathan C, Xie QW. Nitric oxide synthases: Roles, tolls, and controls. Cell. 1994;78:915-918.
41. Nathan C, Xie QW. Regulation of biosynthesis of nitric oxide. J Biol Chem. 1994;269:13725-13728.
42. Magazine HI. Detection of endothelial cell-derived nitric oxide: Current trends and future directions. Adv Neuroimmunol. 1995;5:479-490.
43. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med. 1993;119:771-778.
44. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet. 1987;1:355-357.